Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metastasis of unknown origin.

C M Haskell1, A J Cochran, S H Barsky

  • 1UCLA School of Medicine.

Current Problems in Cancer
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report'.

The British journal of dermatology·2015
Same author

The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin.

Oncogene·2012
Same author

A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling.

British journal of cancer·2011
Same author

Chemotherapy in breast cancer.

Proceedings of the Royal Society of Medicine·2010
Same author

The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction.

Oncogene·2010
Same author

ERalpha signaling through slug regulates E-cadherin and EMT.

Oncogene·2010
Same journal

When should the medical oncologist call the surgeon?

Current problems in cancer·2026
Same journal

Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

Current problems in cancer·2026
Same journal

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

Current problems in cancer·2026
Same journal

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same journal

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

Current problems in cancer·2026
Same journal

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancer·2026
See all related articles

Metastasis of unknown origin (MUO) is a challenging cancer diagnosis. Early diagnosis and targeted therapies, especially for lymph node metastasis, can improve patient outcomes.

Area of Science:

  • Oncology
  • Cancer Metastasis Research

Background:

  • Metastasis of unknown origin (MUO) accounts for 5-10% of noncutaneous cancers.
  • MUO is defined as metastatic cancer where the primary site remains unidentified after thorough evaluation.
  • MUO presents distinct challenges in diagnosis and treatment planning.

Purpose of the Study:

  • To review biochemical events in metastasis as potential therapeutic targets.
  • To emphasize the critical role of accurate tissue diagnosis using various histochemical and molecular techniques.
  • To discuss the management strategies for different MUO subtypes.

Main Methods:

  • Review of biochemical pathways involved in cancer metastasis.
  • Evaluation of diagnostic tools including histochemistry, electron microscopy, and immunohistochemistry.

Related Experiment Videos

  • Analysis of radiologic tests and biomarkers for primary tumor localization.

    • Main Results:

    • Prognosis varies significantly based on MUO site; lymph node involvement in specific areas offers a better outlook.
    • Certain primary tumors (e.g., leukemia-lymphoma, germ cell tumors, adenocarcinomas) show sensitivity to chemotherapy.
    • Advanced poorly differentiated carcinoma of unknown primary origin may respond to cisplatin-based chemotherapy.

    Conclusions:

    • Accurate tissue diagnosis is paramount for effective MUO management.
    • Limited but targeted investigations for specific responsive primary tumors are warranted.
    • Treatment strategies should be tailored to MUO subtypes, considering prognosis and therapeutic sensitivities.